Hope S. Rugo, MD
Despite international guidelines and data that show CDK4/6 inhibitors plus aromatase inhibitors can improve overall response rates, overall survival, and progression-free survival in patients with metastatic breast cancer, there is a lasting belief among patients that chemotherapy is the preferable course of treatment. Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy.
Related Items
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Breast Cancer
Working Together to Find the New Standard of Care
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Opportunities Are Abundant for Navigators in the Field of Genetics and Genomics
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Healthcare Team's Relationship to the Patient
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
The Navigator's Role in Genetic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Why Are Clinical Trials Important?
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Educating Oncology Professionals on Genetic and Genomic Testing
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Who Should Consider Genetic Testing?
Andrey Antov, PhD, MBA
Video Library published on September 6, 2018 in Video
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
What the Next Generation of Cancer Biomarkers May Involve
Sanjiv Agarwala, MD
Video Library published on July 25, 2018 in 2018 ASCO Insights, Video
Last modified: December 7, 2017